125 related articles for article (PubMed ID: 26568877)
1. Urolastic for the treatment of women with stress urinary incontinence: 24-month follow-up.
Zajda J; Farag F
Cent European J Urol; 2015; 68(3):334-8. PubMed ID: 26568877
[TBL] [Abstract][Full Text] [Related]
2. Urolastic-a new bulking agent for the treatment of women with stress urinary incontinence: outcome of 12 months follow up.
Zajda J; Farag F
Adv Urol; 2013; 2013():724082. PubMed ID: 24454351
[TBL] [Abstract][Full Text] [Related]
3. Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis.
Capobianco G; Azzena A; Saderi L; Dessole F; Dessole S; Sotgiu G
Int Urogynecol J; 2018 Sep; 29(9):1239-1247. PubMed ID: 29934769
[TBL] [Abstract][Full Text] [Related]
4. Para-Urethral Injections with Urolastic® for Treatment of Female Stress Urinary Incontinence: Subjective Improvement and Safety.
de Vries AM; van Breda HMK; Fernandes JG; Venema PL; Heesakkers JPFA
Urol Int; 2017; 99(1):91-97. PubMed ID: 28152525
[TBL] [Abstract][Full Text] [Related]
5. Results of an innovative bulking agent in patients with stress urinary incontinence who are not optimal candidates for mid-urethral sling surgery.
Kowalik CR; Casteleijn FM; van Eijndhoven HWF; Zwolsman SE; Roovers JWR
Neurourol Urodyn; 2018 Jan; 37(1):339-345. PubMed ID: 28452427
[TBL] [Abstract][Full Text] [Related]
6. Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review.
Hoe V; Haller B; Yao HH; O'Connell HE
Neurourol Urodyn; 2021 Aug; 40(6):1349-1388. PubMed ID: 34015151
[TBL] [Abstract][Full Text] [Related]
7. An Open Multicenter Study of Clinical Efficacy and Safety of Urolastic, an Injectable Implant for the Treatment of Stress Urinary Incontinence: One-Year Observation.
Futyma K; Miotła P; Gałczyński K; Baranowski W; Doniec J; Wodzisławska A; Jóźwik M; Oniszczuk M; Rechberger T
Biomed Res Int; 2015; 2015():851823. PubMed ID: 26106616
[TBL] [Abstract][Full Text] [Related]
8. Nonabsorbable urethral bulking agent - clinical effectiveness and late complications rates in the treatment of recurrent stress urinary incontinence after 2 years of follow-up.
Futyma K; Nowakowski Ł; Gałczyński K; Miotła P; Rechberger T
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():68-72. PubMed ID: 27825030
[TBL] [Abstract][Full Text] [Related]
9. Can urethral re-bulking improve the outcomes of a prior urethral bulking?
Giammò A; Ammirati E; Geretto P; Manassero A; Squintone L; Falcone M; Del Popolo G; Pistolesi D; Risi O; Costantini E; Giannantoni A; Mancini V; Li Marzi V; Agrò EF; Pastorello M; Musco S; Gontero P
Ther Adv Urol; 2022; 14():17562872211069265. PubMed ID: 35069806
[TBL] [Abstract][Full Text] [Related]
10. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results.
Ghoniem G; Corcos J; Comiter C; Westney OL; Herschorn S
J Urol; 2010 Apr; 183(4):1444-9. PubMed ID: 20171691
[TBL] [Abstract][Full Text] [Related]
11. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere.
Lightner D; Calvosa C; Andersen R; Klimberg I; Brito CG; Snyder J; Gleason D; Killion D; Macdonald J; Khan AU; Diokno A; Sirls LT; Saltzstein D
Urology; 2001 Jul; 58(1):12-5. PubMed ID: 11445471
[TBL] [Abstract][Full Text] [Related]
12. Urethral Bulking in the Treatment of Stress and Mixed Female Urinary Incontinence: Results from a Multicenter Cohort and Predictors of Clinical Outcomes.
Giammò A; Geretto P; Ammirati E; Manassero A; Squintone L; Falcone M; Costantini E; Del Popolo G; Finazzi Agrò E; Giannantoni A; Li Marzi V; Mancini V; Musco S; Pastorello M; Pistolesi D; Risi O; Gontero P
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329895
[TBL] [Abstract][Full Text] [Related]
13. Comparison between porcine dermal implant (Permacol) and silicone injection (Macroplastique) for urodynamic stress incontinence.
Bano F; Barrington JW; Dyer R
Int Urogynecol J Pelvic Floor Dysfunct; 2005; 16(2):147-50; discussion 150. PubMed ID: 15378234
[TBL] [Abstract][Full Text] [Related]
14. Update on Urethral Bulking for Stress Urinary Incontinence in Women.
Zheng Y; Rovner E
Curr Urol Rep; 2022 Oct; 23(10):203-209. PubMed ID: 35781870
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety and efficacy of a monopolar nonablative radiofrequency device for the improvement of vulvo-vaginal laxity and urinary incontinence.
Lalji S; Lozanova P
J Cosmet Dermatol; 2017 Jun; 16(2):230-234. PubMed ID: 28556393
[TBL] [Abstract][Full Text] [Related]
16. Bulking agents for stress urinary incontinence: short-term results and complications in a randomized comparison of periurethral and transurethral injections.
Schulz JA; Nager CW; Stanton SL; Baessler K
Int Urogynecol J Pelvic Floor Dysfunct; 2004; 15(4):261-5. PubMed ID: 15517671
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of polydimethylsiloxane (Macroplastique®) in women with stress urinary incontinence: analysis of data from patients who completed three years follow-up.
Ghoniem G; Farhan B; Chowdhury ML; Chen Y
Int Urogynecol J; 2021 Oct; 32(10):2835-2840. PubMed ID: 34100973
[TBL] [Abstract][Full Text] [Related]
18. Urethral bulking agents for female stress urinary incontinence.
Hussain SM; Bray R
Neurourol Urodyn; 2019 Mar; 38(3):887-892. PubMed ID: 30801773
[TBL] [Abstract][Full Text] [Related]
19. Bulkamid (PAHG) in mixed urinary incontinence: What is the outcome?
Mohr S; Marthaler C; Imboden S; Monga A; Mueller MD; Kuhn A
Int Urogynecol J; 2017 Nov; 28(11):1657-1661. PubMed ID: 28417154
[TBL] [Abstract][Full Text] [Related]
20. [Vaginal reconstruction for the remedy of pelvic organ prolapse: the effect, influence on urinary and sexual function and quality of life in two-years follow-up Part II - Urinary tract: function and complications].
Čadková I; Huvar I
Ceska Gynekol; 2018; 83(2):94-102. PubMed ID: 29869506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
